Ara Metjian, MD

Professional Titles

• Associate Professor

Research Interests

I have an active interest in all aspects of Benign Hematology, particularly in congenital bleeding disorders and acquired diseases of hemostasis, such as thrombotic microangiopathies and immune-mediated cytopenias. These conditions are rare and often occur in under-represented populations, which makes their research and development even more necessary. By offering a wide array of clinical trials for these disease states, we can move care forward and offer improved therapies

Publications

• Yuan X, Yu J, Gerber G, Chaturvedi S, Cole M, Chen H, Metjian A, Sperati CJ, Braunstein EM, Brodsky RA. Ex vivo assays to detect complement activation in complementopathies. Clin Immunol. 2020 Dec;221:108616. PubMed PMID: 33148511
• Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020;11:2040620720902904. PubMed PMID: 32095224
• Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020 Feb;18(2):479-484. PubMed PMID: 31691462
• Josephson CD, Goldstein S, Askenazi D, Cohn CS, Spinella PC, Metjian A, Fasano RM, Music-Aplenc L. Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study. Transfusion. 2021 Dec 20. [Epub ahead of print] PubMed PMID: 34931321
• Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021 Apr 27;5(8):2137-2141. PubMed PMID: 33881463
• Metjian A. iTTP: more long-term consequences. Blood. 2023 Jan 19;141(3):216-217. PubMed PMID: 36656614
• Scully M, de la Rubia J, Pavenski K, Metjian A, Knöbl P, Peyvandi F, Cataland S, Coppo P, Kremer Hovinga JA, Minkue Mi Edou J, De Passos Sousa R, Callewaert F, Gunawardena S, Lin J. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. J Thromb Haemost. 2022 Dec;20(12):2810-2822. PubMed PMID: 36138517
• Shah H, Chen H, Pan XZ, Metjian A, Brodsky RA, Braunstein EM, Chaturvedi S. C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy. Blood Adv. 2022 Dec 13;6(23):6071-6074. PubMed PMID: 35914225
• Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA. Race, rituximab, and relapse in TTP. Blood. 2022 Sep 22;140(12):1335-1344. PubMed PMID: 35797471
• Josephson CD, Goldstein S, Askenazi D, Cohn CS, Spinella PC, Metjian A, Fasano RM, Music-Aplenc L. Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study. Transfusion. 2022 Feb;62(2):396-405. PubMed PMID: 34931321
• Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY. A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry. Blood Adv. 2024 Feb 13;8(3):620-623. PubMed PMID: 38100454
• Tarantino MD, Hardesty B, Metjian A, Ortel TL, Chen J, Badejo K, Ma A, Cuker A, Rajasekhar A, Friedman KD, Janbain M. Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study. Haemophilia. 2023 Sep;29(5):1259-1268. PubMed PMID: 37584309
• Metjian A. iTTP: more long-term consequences. Blood. 2023 Jan 19;141(3):216-217. PubMed PMID: 36656614

Professional Memberships

• American Society of Hematology, Member
• American Society for Apheresis, Member
• International Society of Thrombosis and Hemostasis, Member

Practice Locations

UCHealth Hematology Clinic - Anschutz Medical Campus
1665 Aurora Ct
2nd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation

• University of Colorado Hospital

Center Affiliations

• University of Colorado Cancer Center

Specialty Information

Specialties

• Hematology, Board Certification

Conditions & Treatments

• Blood / Lymphatic System - Bleeding Disorders
• Blood / Lymphatic System
• Blood / Lymphatic System - Blood Disorders
• Blood / Lymphatic System - Clotting Disorders